Table 1 Comparison of baseline characteristics and clinical reproductive outcomes

Maternal age (years), mean [IQR]

36 [31 - 42]

36 [31 - 42]

36 [32 - 40]

p = 0.954

ns

Female indication for ART, n (%)

p = 0.483

ns

 Premature ovarian failure and cycle with donated oocytes

2 (7.14%)

0 (0%)

2 (15.38%)

 Normal reproductive function / idiopathic infertility

11 (39.28%)

5 (33.33%)

6 (46.15%)

 Premature ovarian failure

3 (10.71%)

2 (13.33%)

1 (7.69%)

 Non-obstructive tubal lesion

1 (3.57%)

0 (0%)

1 (7.69%)

 Bilateral salpingectomy / cycle with donated oocytes

1 (3.57%)

1 (6.67%)

0 (0%)

 Genetic malformation

1 (3.57%)

1 (6.67%)

0 (0%)

 Endometriosis

2 (7.14%)

1 (6.67%)

1 (7.69%)

 Endometriosis / cycle with donated oocytes

1 (3.57%)

1 (6.67%)

0 (0%)

 Anovulation

4 (14.28%)

3 (20%)

1 (7.69%)

 Cycle with donated oocytes

2 (7.14%)

1 (6.67%)

1 (7.69%)

Male indication for ART, n (%)

p = 0.258

ns

 Cycle with donated semen

2 (7.14%)

1 (6.67%)

1 (7.69%)

 Normozoospermia

15 (53.57%)

8 (53.33%)

7 (53.85%)

 Teratozoospermia

3 (10.71%)

1 (6.67%)

2 (15.38%)

 Criptozoospermia

3 (10.71%)

1 (6.67%)

2 (15.38%)

 Oligoteratozoospermia

1 (3.57%)

0 (0%)

1 (7.69%)

 Astenoteratozoospermia

1 (3.57%)

1 (6.67%)

0 (0%)

 Oligoastenozoospermia

1 (3.57%)

1 (6.67%)

0 (0%)

 Criptozoospermia / cycle with donated semen

1 (3.57%)

1 (6.67%)

0 (0%)

 Astenozoospermia

1 (3.57%)

1 (6.67%)

0 (0%)

Cycle-associated characteristics

 COS protocol, n (%)

p = 0.861

ns

 No COS

6 (21.43%)

3 (20%)

3 (23.08%)

 FSH only

12 (42.86%)

6 (40%)

6 (46.15%)

 FSH + hMG

6 (21.43%)

3 (20%)

3 (23.08%)

 FSH + LH

4 (14.29%)

3 (20%)

1 (7.69%)

Duration of stimulation (days), mean [IQR]

11 [7 - 19]

12 [10 - 19]

10 [7 - 15]

p = 0.115

ns

Daily FSH dose (IU/day), mean [IQR]

264 [84—360]

290.8 [84—360]

235 [100—300]

0.053

ns

Total FSH dose during stimulation (IU), mean [IQR]

2909 [1200—4200]

3383 [1592—4200]

2340 [1200—3600]

p = 0.005

**

Total hMG dose during stimulation (IU), mean [IQR]

282 [0—1500]

247.9 [0—1500]

322.5 [0—1500]

p = 0.858

ns

Total LH dose during stimulation (IU), mean [IQR]

266 [0—2100]

350 [0—2100]

165 [0—1650]

p = 0.444

ns

Fertilization technique, n (%)

NA

NA

 ICSI

28 (100%)

15 (100%)

13 (100%)

Embryo state, n (%)

p = 0.232

ns

 Fresh

25 (89.29%)

13 (86.67%)

12 (92.31%)

 Frozen

3 (10.71%)

2 (13.33%)

1 (7.69%)

Blastocyst stage, n (%)

p = 0.630

ns

 BC

1 (3.57%)

1 (6.67%)

0 (0%)

 BE

24 (85.71%)

13 (86.67%)

11 (84.62%)

 BHi

3 (10.71%)

1 (6.67%)

2 (15.38%)

Quality of transferred blastocyst, n (%)

p = 0.118

ns

 aa

1 (3.57%)

0 (0%)

1 (7.69%)

 ab

2 (7.14%)

2 (13.33%)

0 (0%)

 bb

14 (50%)

7 (46.67%)

7 (53.85%)

 bc

6 (21.43%)

5 (33.33%)

1 (7.69%)

 cc

5 (17.86%)

1 (6.67%)

4 (30.77%)

Quality of ICM, n (%)

p = 0.246

ns

 A

3 (10.71%)

2 (13.33%)

1 (7.69%)

 B

20 (71.43%)

12 (80%)

8 (61.54%)

 C

5 (17.86%)

1 (6.67%)

4 (30.77%)

Quality of TE, n (%)

p = 0.547

ns

 A

1 (3.57%)

0 (0%)

1 (7.69%)

 B

16 (57.14%)

9 (60%)

7 (53.85%)

 C

11 (39.29%)

6 (40%)

5 (38.46%)

Clinical Outcomes

 Implantation rate, n (%)

15 (53.57%)

NA

NA

NA

 Biochemical pregnancy rate, n (%)

1 (6.67%)

NA

NA

NA

 Clinical pregnancy rate, n (%)

14 (93.33%)

NA

NA

NA

 Clinical miscarriage rate, n (%)

3 (21.43%)

NA

NA

NA

 Live birth rate, n (%)

11 (78.57%)

NA

NA

NA